Retrospective efficacy analysis of olaparib combined with bevacizumab in the treatment of advanced colorectal cancer  

作　　者：Yi-Ling Jiang Xue-Yuan Fu Zhi-Hui Yin 

机构地区：[1]Department of Oncology,The First Affiliated Hospital,Hengyang Medical School,University of South China,Hengyang 421001,Hunan Province,China [2]Department of Anorectal,The First Affiliated Hospital,Hengyang Medical School,University of South China,Hengyang 421001,Hunan Province,China

出　　处：《World Journal of Gastrointestinal Surgery》2023年第5期906-916,共11页世界胃肠外科杂志（英文版）（电子版）

摘　　要：BACKGROUND Colorectal cancer(CRC)is a highly prevalent malignancy of the digestive tract worldwide,characterized by a significant morbidity and mortality rate and subtle initial symptoms.Diarrhea,local abdominal pain,and hematochezia occur with the development of cancer,while systemic symptoms such as anemia and weight loss occur in patients with advanced CRC.Without timely interventions,the disease can have fatal consequences within a short span.The current therapeutic options for colon cancer include olaparib and bevacizumab,which are widely utilized.This study intends to evaluate the clinical efficacy of olaparib combined with bevacizumab in the treatment of advanced CRC,hoping to provide insights into advanced CRC treatment.AIM To investigate the retrospective efficacy of olaparib combined with bevacizumab in the treatment of advanced CRC.METHODS A retrospective analysis was conducted on a cohort of 82 patients with advanced colon cancer who were admitted to the First Affiliated Hospital of the University of South China between January 2018 and October 2019.Among them,43 patients subjected to the classical FOLFOX chemotherapy regimen were selected as the control group,and 39 patients undergoing treatment with olaparib combined with bevacizumab were selected as the observation group.Subsequent to different treatment regimens,the short-term efficacy,time to progression(TTP),and incidence rate of adverse reactions between the two groups were compared.Changes in serum-related indicators[vascular endothelial growth factor(VEGF),matrix metalloprotein-9(MMP-9),cyclooxygenase-2(COX-2)]and tumor markers[human epididymis protein 4(HE4),carbohydrate antigen 125(CA125),carbohydrate antigen 199(CA199)]levels before and after treatment were compared between the two groups at the same time.RESULTS The objective response rate was discovered to be 82.05%,and the disease control rate was 97.44%in the observation group,which were significantly higher than the respective rates of 58.14%and 83.72%in the control group(P<0.05).The

关 键 词：OLAPARIB BEVACIZUMAB Advanced colorectal cancer EFFICACY 

分 类 号：R735.34[医药卫生—肿瘤]